calculus in human body all type and all segment each and every treatment drug dosage

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Here is a comprehensive reference on all types of calculi (stones) found in the human body, their anatomical locations, stone compositions, and complete treatments including drug dosages.

Calculi in the Human Body: All Types, Locations, and Treatments

1. URINARY TRACT CALCULI (Urolithiasis)

Urinary stones are the most common type of calculi, affecting ~12% of the population lifetime. They are classified by anatomical segment and composition.

1A. Renal Calculi (Nephrolithiasis)

Location: Renal pelvis, calyces, renal parenchyma (nephrocalcinosis)

Types by Composition:

Stone Type	Frequency	Key Features
Calcium oxalate (monohydrate/dihydrate)	~60-70%	Radiopaque, hard, spiky; most common overall
Calcium phosphate (hydroxyapatite, brushite)	~10-20%	Radiopaque; associated with RTA, hyperparathyroidism
Uric acid	~5-10%	Radiolucent on plain X-ray; low pH urine
Struvite (magnesium ammonium phosphate)	~5-15%	"Staghorn" calculi; urease-splitting bacteria (Proteus, Klebsiella)
Cystine	~1-2%	Radiopaque; autosomal recessive cystinuria
Mixed/Other	~5%	Combination types

Acute Management - Renal Colic:

Drug	Dose	Route	Notes
Ketorolac (NSAID)	15-30 mg IV/IM q6h	IV/IM	First-line analgesic; reduces ureteral spasm
Ibuprofen	400-600 mg q6-8h	PO	For mild-moderate pain
Diclofenac	75 mg	IM	Effective for acute colic
Morphine	0.05-0.1 mg/kg IV	IV	For severe pain unresponsive to NSAIDs
Ondansetron	4-8 mg IV/IM	IV/IM	Antiemetic
Metoclopramide	10 mg IV	IV	Antiemetic

Medical Expulsive Therapy (MET) - to facilitate stone passage:

Drug	Dose	Notes
Tamsulosin (alpha-1 blocker)	0.4 mg once daily	First-line MET; relaxes ureteral smooth muscle; best for distal ureteral stones >5 mm; 4-6 weeks trial
Nifedipine (CCB)	30 mg once daily (extended release)	Alternative to tamsulosin; less preferred
Silodosin	8 mg once daily	Alternative alpha-1 blocker

Both AUA and EAU guidelines recommend alpha blockers for distal ureteral stones. AUA: stones <10 mm; EAU: stones >5 mm. 4-6 weeks of observation with MET is appropriate before procedural intervention.

Long-term Pharmacologic Prevention (by stone type):

Calcium Oxalate / Calcium Phosphate Stones

Drug	Dose	Indication	Evidence
Hydrochlorothiazide	25-50 mg/day	Hypercalciuria	50% reduction in recurrence in RCTs
Chlorthalidone	25 mg/day	Hypercalciuria	Preferred in some guidelines
Potassium citrate	30-60 mEq/day in divided doses (e.g., 10-20 mEq TID)	Hypocitraturia, calcium stones	>50% reduction in recurrence; preferred over sodium citrate
Potassium bicarbonate	25-50 mEq/day	Hypocitraturia	Alternative to citrate
Allopurinol	100-300 mg/day	Calcium oxalate with hyperuricosuria	50% reduction in recurrence

Note: Thiazides require sodium restriction (<3 g/day) to achieve maximum benefit. Studies used HCTZ 50 mg or chlorthalidone 25 mg; doses higher than typical antihypertensive doses.

Uric Acid Stones

Drug	Dose	Notes
Potassium citrate	30-60 mEq/day in divided doses	Urinary alkalinization target pH 6.5-7.0; first-line
Sodium bicarbonate	650 mg-1 g TID-QID	Alternative alkalinizing agent
Allopurinol	100-300 mg/day	Reduces urine uric acid by 40-50%; used when alkalinization alone fails or diet modification insufficient
Febuxostat	40-80 mg/day	Alternative xanthine oxidase inhibitor when allopurinol not tolerated

Struvite Stones

Approach	Details
Surgical removal (PCNL)	Complete stone removal mandatory; stones cannot dissolve medically
Acetohydroxamic acid (AHA)	250 mg TID-QID (max 1.5 g/day); urease inhibitor; adjunct to surgery; significant side effects limit use
Long-term low-dose antibiotics	After surgical removal, to prevent recurrent urinary infections

Cystine Stones

Drug	Dose	Notes
High fluid intake	Target urine output >3 L/day	Most important measure
Potassium citrate	30-60 mEq/day	Alkalinize urine to pH >7.5
D-penicillamine	1-2 g/day in divided doses	Forms soluble penicillamine-cysteine disulfide; side effects significant (rash, proteinuria)
Tiopronin (alpha-mercaptopropionylglycine)	800-1200 mg/day in divided doses	Better tolerated than D-penicillamine; preferred
Captopril	75-150 mg/day	Used when other agents not tolerated; weaker evidence

Primary Hyperoxaluria (rare genetic cause)

Drug	Dose	Notes
Pyridoxine (B6)	5-20 mg/kg/day	For PH type 1 (AGXT mutation); reduces oxalate production in responders (~20%)
Lumasiran (RNA interference)	SC injection per protocol	FDA-approved 2020 for PH type 1; reduces hepatic oxalate production
Potassium citrate	Standard dosing	Supportive

1B. Ureteral Calculi

Location: Upper, mid, or distal ureter

Ureteral stones are almost always renal stones that have migrated. Composition is the same as above.

Key facts:

Stones <4 mm: ~80% pass spontaneously
Stones 4-6 mm: ~50% pass spontaneously
Stones >6 mm: <20% pass spontaneously

Treatment:

Acute: NSAIDs + opioids for pain (as above)
MET: Tamsulosin 0.4 mg/day for 4-6 weeks (especially for distal stones)
Procedural: Ureteroscopy with laser lithotripsy (Ho:YAG laser); ESWL for proximal stones
Emergency: Ureteral stenting or percutaneous nephrostomy for obstructing stones with infection or single kidney

1C. Bladder Calculi (Vesical Calculi)

Location: Urinary bladder

Composition: Uric acid (especially "jackstone" shape), struvite, calcium oxalate, calcium phosphate

Risk factors: Bladder outlet obstruction (BPH), neurogenic bladder, indwelling catheters, bladder diverticula, urinary stasis

Treatment:

Cystoscopy with electrohydraulic or ultrasonic lithotripsy (fragmentation)
Open cystolithotomy for large stones
Treat the underlying cause (e.g., TURP for BPH)
Medical: Treat UTI; correct metabolic factors

Bladder calculi associated with BPH should be treated before or simultaneously with the prostatic surgery.

1D. Urethral Calculi

Location: Most common in the prostatic or bulbar urethra (men); rare in women (usually associated with urethral diverticulum)

Sources: Usually migrate from the bladder

Symptoms: Interrupted stream, terminal hematuria, pain radiating to tip of penis

Treatment:

Small stones: Cystoscopic extraction or retrograde manipulation into bladder then fragmentation
Large impacted stones: Open urethrotomy
Stones with diverticulum/stricture: Open surgical repair

1E. Urinary Stones in Special Populations

Pregnancy:

Most stones are calcium phosphate (different from non-pregnant)
64-84% pass spontaneously - conservative management first
Analgesics, hydration, position lateral decubitus (symptomatic side up)
Nifedipine 30 mg/day can be used (safe in pregnancy for tocolysis/hypertension)
Avoid NSAIDs in third trimester
Imaging: Ultrasound first; MR urography if needed; limited IVU if necessary; CT acceptable if diagnosis uncertain (radiation below teratogenic threshold)
Ureteral stenting or ureteroscopy if conservative management fails

Renal Transplant Recipients:

Incidence ~1%; mean onset 28 months post-transplant
Mostly calcium-based (67%), struvite (20%), uric acid (13%)
Treatment follows native kidney algorithm
Metabolic screening mandatory to identify treatable causes

2. BILIARY CALCULI (Cholelithiasis)

Location: Gallbladder, cystic duct, common bile duct (choledocholithiasis), intrahepatic bile ducts

Types:

Type	Frequency	Composition	Risk Factors
Cholesterol stones	~80-90% (Western)	>50% crystalline cholesterol monohydrate	Female sex, obesity, pregnancy, oral contraceptives, rapid weight loss, advancing age, hyperlipidemia, metabolic syndrome
Black pigment stones	~10-15%	Bilirubin calcium salts (sterile bile)	Chronic hemolysis (sickle cell, spherocytosis), cirrhosis, total parenteral nutrition
Brown pigment stones	~5%	Calcium bilirubinate + calcium soaps	Biliary infection, bile stasis, parasites (Clonorchis), biliary strictures

Risk factor genetics: ABCG8 gene variant (sterol transporter) increases cholesterol gallstone risk.

Treatment:

Situation	Treatment
Asymptomatic gallstones	Watchful waiting in most; prophylactic cholecystectomy in selected (porcelain gallbladder, sickle cell, morbid obesity pre-bariatric surgery)
Symptomatic cholelithiasis	Laparoscopic cholecystectomy - gold standard
Acute cholecystitis	IV antibiotics (cefazolin, ceftriaxone, metronidazole for severe) + laparoscopic cholecystectomy (early, within 72h) or percutaneous cholecystostomy in high surgical risk
Choledocholithiasis (CBD stones)	ERCP with sphincterotomy and stone extraction, followed by cholecystectomy
Acute cholangitis	IV antibiotics (piperacillin-tazobactam 3.375 g q6h IV, or ceftriaxone 1-2 g/day + metronidazole) + urgent ERCP for biliary decompression

Medical (Non-surgical) Dissolution Therapy:

Drug	Dose	Notes
Ursodeoxycholic acid (UDCA / ursodiol)	15 mg/kg/day in divided doses	For small (<5 mm), radiolucent, non-calcified cholesterol stones in functioning gallbladder; dissolves stones in only ~30-40% over 6-24 months; stones recur in ~50% after stopping
Ursodiol (prevention)	300 mg twice daily x 6 months post-bariatric surgery	Reduces gallstone formation to ~3%
Ursodiol (during rapid weight loss)	15 mg/kg/day	Prophylaxis during rapid weight loss or long-term somatostatin analogue therapy

Note: Medical dissolution is rarely used today due to limited efficacy and the widespread availability of laparoscopic cholecystectomy.

3. SALIVARY GLAND CALCULI (Sialolithiasis)

Location and Frequency:

Submandibular gland / Wharton's duct: 80-90% of cases
Parotid gland / Stensen's duct: 10-20% of cases
Sublingual gland: ~1% of cases

Composition: Calcium phosphate and carbonate combined with an organic matrix of glycoproteins and mucopolysaccharides; small amounts of magnesium, potassium, and ammonium.

Why submandibular is most common: Wharton's duct is longer, wider, more tortuous, courses against gravity around the mylohyoid muscle, and the gland produces more viscous saliva with higher calcium/phosphorous content.

Symptoms: Recurrent postprandial salivary colic (pain and swelling worse with eating), suppurative sialadenitis episodes, foul-tasting discharge on gland massage.

Diagnosis: Ultrasound (detects 90% of stones >2 mm), CT scan (best overall), MRI sialography, conventional sialography.

Treatment:

Stone Size/Location	Treatment
Small duct stones (<3-4 mm, near orifice)	Conservative: massage, hydration, sialogogues (lemon drops, citric acid), heat; manual milking of stone out of duct orifice
Medium stones (4-7 mm)	Sialendoscopy (minimally invasive endoscopic removal); basket or grasper extraction
Large or impacted stones (>7-8 mm)	Extracorporeal shock wave lithotripsy (ESWL) - 2-5 sessions; combined sialendoscopy + ESWL
Stones in gland parenchyma or recurrent sialadenitis	Surgical: transoral duct incision (for anterior stones); sialadenectomy (gland removal) for recurrent disease or stones not accessible endoscopically

Drug therapy: No specific stone-dissolving drugs. Antibiotics (amoxicillin-clavulanate 875/125 mg BID, or clindamycin for penicillin allergy) for acute suppurative sialadenitis. NSAIDs for pain.

4. PANCREATIC CALCULI (Pancreatolithiasis)

Location: Main pancreatic duct, side branches, pancreatic parenchyma

Composition: Calcium carbonate (predominantly); form when calcium carbonate precipitates in inspissated proteinaceous plugs within pancreatic ducts.

Association: Almost always associated with chronic pancreatitis. Stones obstruct the pancreatic duct and are large relative to the duct diameter, making endoscopic removal more technically difficult than bile duct stones.

Symptoms: Intermittent severe abdominal pain, recurrent acute pancreatitis superimposed on chronic pancreatitis.

Treatment:

Approach	Details
Endoscopic (ERCP)	Pancreatic sphincterotomy + balloon/basket extraction; works for small, non-impacted stones
ESWL	Required for large/impacted stones to fragment them before ERCP extraction; overall 70% complete duct clearance; 2-5 sessions typically needed
Combined ESWL + ERCP	Most effective for large stones
Intraductal lithotripsy	Pancreatoscopy + electrohydraulic or laser lithotripsy for stones not amenable to ESWL/ERCP
Pancreatic stenting	For concomitant ductal strictures; multiple plastic stents, upsized over time; 90% stricture resolution with multi-stent approach; 75% remain asymptomatic at 10 years
Surgery	Lateral pancreaticojejunostomy (Frey or Puestow procedure) or Whipple for failed endoscopic therapy or refractory disease

Drug therapy: No drugs dissolve pancreatic stones. Pain management with analgesics (acetaminophen, NSAIDs, opioids for severe pain). Pancreatic enzyme replacement for exocrine insufficiency. Abstinence from alcohol is critical.

5. PROSTATIC CALCULI

Location: Acini (glandular tissue) of the prostate

Types:

Primary/endogenous (corpora amylacea - formed from prostatic secretions around sloughed epithelial cells)
Secondary/exogenous (reflux of urine into prostate ducts)

Composition: Calcium phosphate (83%), calcium carbonate phosphate (8.7%), calcium oxalate (4.5%), mixed (4.4%)

Clinical significance: Usually asymptomatic; discovered incidentally on TRUS, pelvic X-ray, or during prostatectomy. May be associated with chronic prostatitis or carcinoma. Large calculi can mimic prostate carcinoma. Rarely cause LUTS or bladder outlet obstruction.

Treatment:

Most require no treatment
If associated with chronic prostatitis: prolonged antibiotic course (fluoroquinolones e.g., ciprofloxacin 500 mg BID x 4-6 weeks or trimethoprim-sulfamethoxazole)
Rarely: TURP or surgical removal if causing significant symptoms
If causing bladder outlet obstruction: treat prostatic obstruction first

6. SEMINAL VESICLE STONES

Location: Seminal vesicles (extremely rare)

Presentation: Hematospermia, stony hard gland on examination; crunching sensation if multiple stones present. May be confused with seminal vesicle tuberculosis.

Treatment: Surgical excision in symptomatic cases; transrectal ultrasound-guided aspiration in selected cases.

7. URETHRAL AND PREPUTIAL CALCULI

Urethral calculi: Usually migrate from bladder; form near strictures or in diverticula. Treatment: endoscopic extraction, open urethrotomy for large impacted stones.

Preputial calculi: Rare; occur in adults with severe obstructive phimosis and poor hygiene (inspissated smegma). Treatment: dorsal preputial slit or circumcision.

8. DENTAL AND ORAL CALCULI

Dental Calculus (Tartar)

Location: Supragingival (above gumline) and subgingival (below gumline) surfaces of teeth

Composition: Mineralized dental plaque; primarily calcium phosphate salts (hydroxyapatite, octacalcium phosphate, whitlockite, brushite) embedded in an organic matrix.

Treatment:

Professional scaling and root planing (ultrasonic or hand instruments)
No pharmacologic dissolution agents are effective once calcified
Prevention: fluoride toothpastes, antiseptic mouthwashes (chlorhexidine 0.12-0.2% BID)

Pulp Stones (Pulp Calcifications / Denticles)

Location: Dental pulp chamber or root canals

Composition: Dystrophic calcification (hydroxyapatite) around degenerating pulp tissue

Clinical significance: Usually incidental finding on dental X-rays; may complicate endodontic (root canal) treatment

Treatment: Endodontic treatment (root canal) if symptomatic; no drugs dissolve pulp stones

SUMMARY TABLE: Calculi Types and Key Drugs

Calculus Type	Location	Key Drugs / Doses
Calcium oxalate stones	Kidney/ureter	HCTZ 25-50 mg/day; Potassium citrate 30-60 mEq/day; Allopurinol 100-300 mg/day
Calcium phosphate stones	Kidney/ureter	Treat underlying RTA; Potassium citrate; HCTZ
Uric acid stones	Kidney/bladder/ureter	Potassium citrate 30-60 mEq/day (target pH 6.5-7.0); Allopurinol 100-300 mg/day; Febuxostat 40-80 mg/day
Struvite stones	Kidney (staghorn)	Surgery (PCNL); AHA 250 mg TID-QID (adjunct)
Cystine stones	Kidney/ureter	High fluids (>3L/day); K-citrate; Tiopronin 800-1200 mg/day; D-penicillamine 1-2 g/day
Renal colic (acute)	Ureter	Ketorolac 15-30 mg IV; Morphine 0.05-0.1 mg/kg IV; Tamsulosin 0.4 mg/day (MET)
Cholesterol gallstones	Gallbladder/CBD	Laparoscopic cholecystectomy; Ursodiol 15 mg/kg/day (dissolution)
Salivary stones	Submandibular/Parotid duct	Sialendoscopy; ESWL; Antibiotics for sialadenitis
Pancreatic stones	Pancreatic duct	ERCP + ESWL; Surgery; Pain management
Prostatic stones	Prostate acini	Usually no treatment; antibiotics for chronic prostatitis

Sources: Brenner and Rector's The Kidney; Comprehensive Clinical Nephrology 7th Ed.; Harrison's Principles of Internal Medicine 22E; Campbell-Walsh-Wein Urology; National Kidney Foundation Primer on Kidney Diseases 8th Ed.; Robbins & Cotran Pathologic Basis of Disease; Cummings Otolaryngology; Bailey and Love's Surgery; Yamada's Textbook of Gastroenterology; Smith and Tanagho's General Urology.

This is a shared conversation. Sign in to Orris to start your own chat.